Immune OTC Stock Leadership

IMUN -  USA Stock  

USD 2.30  0.60  20.69%

Immune Therapeutics employes about 4 people. The company is managed by 12 executives with total tenure of roughly 70 years, averaging almost 5.0 years of service per executive having 0.33 employees per reported executive. Inspection of Immune Therapeutics management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Immune Therapeutics future performance.
Please see Risk vs Return Analysis.

Immune Insiders 

 
Refresh
  Nicholas Plotnikoff  Chairman
Non-Executive Chairman of the Board
  Noreen Griffin  Chairman
Founder, Chairman and CEO

Immune Therapeutics Management Team Effectiveness

Immune Therapeutics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Immune Therapeutics Workforce Comparison

Immune Therapeutics is rated below average in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 123,202. Immune Therapeutics adds roughly 4.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.

Immune Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immune Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immune Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Immune Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Immune Therapeutics Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Immune Therapeutics Price Series Summation is a cross summation of Immune Therapeutics price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Immune Therapeutics Notable Stakeholders

An Immune Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Immune Therapeutics often face trade-offs trying to please all of them. Immune Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Immune Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Nicholas Plotnikoff - Non-Executive Chairman of the BoardProfile
Noreen Griffin - Founder, Chairman and CEOProfile
Peter Aronstam - CFOProfile
Rudy Williams - COOProfile
Jack Brewer - DirectorProfile
Clifford Selsky - Independent DirectorProfile
Kevin Phelps - DirectorProfile
Edward Teraskiewicz - Independent DirectorProfile
Christopher Pearce - COO, DirectorProfile
Paul Akin - Independent DirectorProfile
Joseph Fortunak - VP of Global RandD and Chemical Devel. and Member of Advisory BoardProfile
Fengping Shan - Chief Science OfficerProfile

About Immune Therapeutics Management Performance

The success or failure of an entity such as Immune Therapeutics often depends on how effective the management is. Immune Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immune management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immune management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Immune Therapeutics, Inc. focuses on the development, approval, and commercialization of pharmaceutical products. Immune Therapeutics, Inc. was incorporated in 1993 and is headquartered in Orlando, Florida. Immune Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
The data published in Immune Therapeutics' official financial statements usually reflect Immune Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Immune Therapeutics. For example, before you start analyzing numbers published by Immune accountants, it's critical to develop an understanding of what Immune Therapeutics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Immune Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immune Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Immune Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immune Therapeutics. Please utilize our Beneish M Score to check the likelihood of Immune Therapeutics' management to manipulate its earnings.

Immune Therapeutics Workforce Analysis

Traditionally, organizations such as Immune Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Immune Therapeutics within its industry.

Immune Therapeutics Manpower Efficiency

Return on Immune Therapeutics Manpower

Revenue Per Employee12.1 K
Revenue Per Executive4 K
Net Income Per Employee792.5 K
Net Income Per Executive264.2 K
Please see Risk vs Return Analysis. Note that the Immune Therapeutics information on this page should be used as a complementary analysis to other Immune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Immune OTC Stock analysis

When running Immune Therapeutics price analysis, check to measure Immune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immune Therapeutics is operating at the current time. Most of Immune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Immune Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immune Therapeutics' price. Additionally, you may evaluate how the addition of Immune Therapeutics to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
The market value of Immune Therapeutics is measured differently than its book value, which is the value of Immune that is recorded on the company's balance sheet. Investors also form their own opinion of Immune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immune Therapeutics' market value can be influenced by many factors that don't directly affect Immune Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immune Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.